Lead Product(s) : Alfacalcidol
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Cheplapharm Arzneimittel Gmbh
Deal Size : $355.0 million
Deal Type : Divestment
Leo Pharma Sells Portfolio of Four Products to Cheplapharm
Details : The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha©, Locoid©, Pimafucin©, and Zineryt©.
Product Name : One-Alpha
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Undisclosed
August 31, 2020
Lead Product(s) : Alfacalcidol
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Cheplapharm Arzneimittel Gmbh
Deal Size : $355.0 million
Deal Type : Divestment
Lead Product(s) : Alfacalcidol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Alberta Innovates Health Solutions | Canadian Institutes of Health Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Vitamin D and Cardiac Autonomic Tone in Hemodialysis
Details : Alfacalcidol is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cardiovascular Diseases.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
January 24, 2013
Lead Product(s) : Alfacalcidol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Alberta Innovates Health Solutions | Canadian Institutes of Health Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
